MedHub-AI has announced a distribution agreement with Terumo Corporation to bring its AutocathFFR artificial intelligence (AI)-powered software to the Japanese market.
Fractional Flow Reserve (FFR) is a commonly used technique in cardiac catheterisation for assessing the extent of blood flow reduction in narrowed coronary arteries.
Traditionally, this procedure involves administering a vasodilatory drug to dilate the blood vessels, followed by the insertion of a guidewire equipped with a pressure sensor into the coronary artery. The sensor measures intravascular pressure changes to determine the FFR value, enabling physicians to assess the severity of arterial blockages.
AutocathFFR calculates precise FFR values, automatically, directly from X-ray coronary angiograms using advanced AI algorithms, eliminating the need for invasive guidewires with a pressure sensor or drug-induced vessel dilation.
“Our partnership with Terumo represents a pivotal moment in the evolution of cardiac care,” said Or Bruch-El, chief executive officer of MedHub-AI. “Together, we are ushering in a new era where AI empowers physicians with unmatched speed, accuracy, and reliability. AutocathFFR overcomes the limitations of traditional and existing 3D-based FFR approaches that often rely on subjective interpretation and operator skill. This is a leap forward toward fully standardised and scalable coronary diagnostics.”
“Terumo offers a variety of medical devices designed for high operability and enhanced therapeutic outcomes for patients, covering the comprehensive process of catheter diagnosis and treatment,” said Mitsuhiro Tanba, general manager, Terumo Interventional Systems Japan, Cardiac and Vascular Company, Terumo Corporation. “With this partnership with MedHub-AI, we will expand our product lineup in the cardiovascular field, offering a wider range of options to healthcare professionals and contributing to the improvement of the quality of life for patients.”
AutocathFFR is built on an advanced AI approach that allows MedHub-AI to continually enhance performance, launch improved software versions, and respond to clinical needs with ever-greater precision and usability, the company says in a press release. It is currently progressing through the final stages of its regulatory pathway and expects to receive US Food and Drug Administration (FDA) approval within months, marking a pivotal milestone toward broader clinical adoption and global market expansion.
